ArticleJournal of oncology practice2015
Projected Clinical, Resource Use, and Fiscal Impacts of Implementing Low-Dose Computed Tomography Lung Cancer Screening in Medicare.
Article in Journal of oncology practice, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 29 citations in OpenAlex.
- Trends in lung cancer burden, risk factors, and disease projections in China and the United States, 1990-2023.Chinese medical journal pulmonary and critical care medicine · 2026Article
- Budget Impact of the LungFlag™ Predictive Risk Model for Lung Cancer Screening.PharmacoEconomics - open · 2026Article
- Health Care Spending on Respiratory Diseases in the United States, 1996-2016.American journal of respiratory and critical care medicine · 2023Article
- Dermatomyositis and malignancy: should all patients with dermatomyositis undergo malignancy screening?Annals of translational medicine · 2021Review
- Article
- Use of Lung Cancer Screening With Low-Dose Computed Tomography in the Medicare Population.Mayo Clinic proceedings. Innovations, quality & outcomes · 2019Article
- Lung Cancer Screening Inconsistent With U.S. Preventive Services Task Force Recommendations.American journal of preventive medicine · 2019Article
- Screening for Lung Cancer Has Limited Effectiveness Globally and Distracts From Much Needed Efforts to Reduce the Critical Worldwide Prevalence of Smoking and Related Morbidity and Mortality.Journal of global oncology · 2018Article
- The Economic Burden of Small Cell Lung Cancer: A Systematic Review of the Literature.PharmacoEconomics - open · 2018Review
- Challenges Implementing Lung Cancer Screening in Federally Qualified Health Centers.American journal of preventive medicine · 2018Article
- Sputum-based DNA methylation biomarkers to guide lung cancer screening decisions.Journal of thoracic disease · 2017Article
- Article
- Lung Cancer Screening.The Medical clinics of North America · 2017Review
- A qualitative analysis of smokers' perceptions about lung cancer screening.BMC public health · 2017Article
- Article
- Electromagnetic navigation bronchoscopy to access lung lesions in 1,000 subjects: first results of the prospective, multicenter NAVIGATE study.BMC pulmonary medicine · 2017Article
- 2016 reflections on the favorable cost-benefit of lung cancer screening.Annals of translational medicine · 2016Review
- Early detection of lung cancer.F1000Research · 2016Review
- Optimizing lung cancer screening: nodule size, volume doubling time, morphology and evaluation of other diseases.Annals of translational medicine · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
purposeThe Centers for Medicare and Medicaid Services (CMS) recently issued a national coverage determination that provides reimbursement for low-dose computed tomography (CT) lung cancer screening for enrollees age 55 to 77 years with ≥ 30-pack-year smoking history who currently smoke or quit in the last 15 years. The clinical, resource use, and fiscal impacts of this change in screening coverage policy remain uncertain.
methodsWe developed a simulation model to forecast the 5-year health outcome impacts of the CMS low-dose CT screening policy in Medicare compared with no screening. The model used data from the National Lung Screening Trial, CMS enrollment statistics and reimbursement schedules, and peer-reviewed literature. Outcomes included counts of screening examinations, patient cases of lung cancer detected, stage distribution, and total and per-enrollee per-month fiscal impact.
resultsOver 5 years, we project that low-dose CT screening will result in 10.7 million more low-dose CT scans, 52,000 more lung cancers detected, and increased overall expenditure of $6.8 billion ($2.22 per Medicare enrollee per month). The most fiscally impactful factors were the average cost-per-screening episode, proportion of enrollees eligible for screening, and cost of treating stage I lung cancer.
conclusionLow-dose CT screening is expected to increase lung cancer diagnoses, shift stage at diagnosis toward earlier stages, and substantially increase Medicare expenditures over a 5-year time horizon. These projections can inform planning efforts by Medicare administrators, contracted health care providers, and other stakeholders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.